EPISODE · Oct 20, 2023 · 12 MIN
Cell Therapy: A New M&A Frontier
from Middle Market Growth Conversations · host Association of Corporate Growth
Cell and gene therapy technologies are ascendent, boosted by new developments in treatments for diseases like ovarian cancer and Parkinson’s disease, and by predictions of a meteoric rise in total market value in the next five years. Fabian Gerlinghaus, the co-founder and CEO of Cellares, a company that has developed a so-called “factory-in-a-box” for cell and gene therapy manufacturing, joins the podcast to share Cellares’ unique approach to developing successful cell therapies, the regulatory landscape and why investors should be watching this sector. *** The Middle Market Growth Conversations podcast is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.acg.org.
What this episode covers
Cell and gene therapy technologies are ascendent, boosted by new developments in treatments for diseases like ovarian cancer and Parkinson’s disease, and by predictions of a meteoric rise in total market value in the next five years. Fabian Gerlinghaus, the co-founder and CEO of Cellares, a company that has developed a so-called “factory-in-a-box” for cell and gene therapy manufacturing, joins the podcast to share Cellares’ unique approach to developing successful cell therapies, the regulatory landscape and why investors should be watching this sector. *** The Middle Market Growth Conversations podcast is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.acg.org.
NOW PLAYING
Cell Therapy: A New M&A Frontier
No transcript for this episode yet